Combination Therapy Showed Promise for Pancreatic Tumors
A pilot study suggests that pairing two treatments may help improve responses in patients with neuroendocrine tumors.
Updated on Sept. 19, 2026 in Cancer
Researchers have found that combining the targeted drug sunitinib with the radiopharmaceutical 177Lu-DOTATATE may enhance tumor response in patients with pancreatic neuroendocrine tumors (pNET). This dual approach was evaluated in a pilot group of patients who had previously undergone other treatments.
Why it matters
Sunitinib serves as both a radiosensitizer and an immunomodulator, potentially improving the effectiveness of peptide receptor radionuclide therapy (PRRT). This approach could offer new treatment options for managing complex pancreatic neuroendocrine cancers.
In a pilot study of pretreated pNET patients, the combination of 7.4 GBq of 177Lu-DOTATATE per cycle and 37.5 mg of daily sunitinib resulted in near-complete or partial responses in five total patients. The findings remain preliminary as they reflect early response assessments rather than long-term clinical outcomes.
The players
177Lu-DOTATATE
A targeted radiopharmaceutical used to treat neuroendocrine tumors by delivering radiation directly to cells expressing somatostatin receptors.
Sunitinib
A multikinase inhibitor medication that blocks several receptors on cancer cells, used in the treatment of various neuroendocrine and renal tumors.
The details
The combination therapy works by leveraging the unique properties of both agents to induce immunogenic cell death. 177Lu-DOTATATE triggers dose-dependent cell cycle arrest and protein cleavage, while sunitinib enhances the release of markers like HMGB1 and increases calreticulin exposure on the tumor surface. This combined biological activity appears to make tumor cells more vulnerable to treatment without activating the body's canonical inflammasome pathways.
Timeline
September 19, 2026: The research study was published.
Health Landscape
This research follows a pattern set by the NETTER-1 clinical trial, which originally established the benchmark for peptide receptor radionuclide therapy in neuroendocrine cancers. By testing combination protocols, the study marks an effort to move beyond single-agent therapies to improve clinical outcomes.
If you or a loved one are managing pancreatic neuroendocrine tumors, this study highlights an area of ongoing research regarding combined therapy protocols. Discuss the potential for clinical trial participation or emerging treatment combinations with your oncologist to see if they align with your care plan.
The takeaway
This pilot study demonstrates that combining specific targeted agents and radiation may boost the anti-tumor immune response in pancreatic neuroendocrine cancer. Patients should track ongoing clinical research in this field and consult with a specialist about emerging dual-therapy approaches.
Further reading
For more information on the evolving standards of care, visit Cancer.
Source note: This article includes information reported by Nature.
